EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial.

Jean-François Timsit 1, 2, 3, * Elie Azoulay 2, 4 Muriel Cornet 5 Jean-Pierre Gangneux 6 Vincent Jullien 7 Aurélien Vésin 2, 8 Edith Schir 9 Michel Wolff 3
* Auteur correspondant
1 Service de Soins Intensifs [Michallon]
2 Outcomerea Organization
3 Unité de Soins Intensifs et de Maladies Infectieuses
4 Unité de Soins Intensifs [Saint-Louis]
5 TheREx
TIMC-IMAG - Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble]
6 Irset - Institut de recherche, santé, environnement et travail
7 U1129 - Epilepsies de l'Enfant et Plasticité Cérébrale
8 Epidémiologie pronostique des cancers et affections graves
9 Pharmacologie
Abstract : BACKGROUND: The potential interest of antifungal treatment of non-immunocompromized patients with sepsis, extra-digestive Candida colonization and multiple organ failure is unknown. It represents three-quarters of antifungals prescribed in Intensive Care Units. It may allow early treatment of invasive fungal infection in the incubation phase but expose patients to unnecessary antifungal treatments with subsequent cost and fungal selection pressure. As early diagnostic tests for invasive candidiasis are still considered to be insufficient, the potential interest in this strategy needs to be demonstrated. METHODS: This prospective multicenter, double blind, randomized-controlled trial is conducted in 23 French Intensive Care Units. All adult patients, mechanically ventilated for more than four days with sepsis of unknown origin and with at least one extradigestive fungal colonization site and multiple organ failure are eligible for randomization. Patients with proven invasive candidiasis are not included. After a complete mycological screening, patients are allocated to receive micafungin 100 mg intravenously once a day or placebo for 14 days. We plan to enroll 260 patients. The main objective is to demonstrate that micafungin increases survival of patients without invasive candidiasis at day 28 as compared to placebo. Other outcomes include day 28 and 90 survival and organ failure evolution. Additionally, pharmacokinetics of micafungin in enrolled patients will be measured and evolution of fungal biomarkers and susceptibility profiles of infecting fungi will also be followed. DISCUSSION: This study will help to provide guidelines for treating non-immunocompromized patients with fungal colonization multiple organ failure and sepsis of unknown origin.Trial registration: Clinicaltrials.gov number NCT01773876.
keyword : Colonization Nosocomial sepsis Candidemia Invasive candidiasis Micafung
Type de document :
Article dans une revue
Trials, BioMed Central, 2013, 14 (1), pp.399. 〈10.1186/1745-6215-14-399〉
Liste complète des métadonnées

Littérature citée [50 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00913515
Contributeur : Ed. Bmc <>
Soumis le : mardi 3 décembre 2013 - 21:03:12
Dernière modification le : samedi 24 mars 2018 - 01:49:16
Document(s) archivé(s) le : lundi 3 mars 2014 - 23:45:25

Fichiers

1745-6215-14-399.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

IMAG | UNIV-PARIS5 | U823 | IRSET | UGA | TIMC-IMAG-THEREX | TIMC-IMAG | IRSET-HIAEC | BIOSIT | UR1-UFR-SVE | USPC | EHESP | IRSET-2 | CEA | UNIV-RENNES

Citation

Jean-François Timsit, Elie Azoulay, Muriel Cornet, Jean-Pierre Gangneux, Vincent Jullien, et al.. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial.. Trials, BioMed Central, 2013, 14 (1), pp.399. 〈10.1186/1745-6215-14-399〉. 〈inserm-00913515〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

523

Téléchargements de fichiers

1754

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD